US2012171208A1PendingUtilityA1

Anti-PRO87299 Antibodies

58
Assignee: CLARK HILARYPriority: Oct 25, 2002Filed: Mar 2, 2012Published: Jul 5, 2012
Est. expiryOct 25, 2022(expired)· nominal 20-yr term from priority
Inventors:Hilary ClarkDaniel L. EatonBernd WranikWenjun OuyangLino GonzalezAustin GurneyKelly Loyet
A61P 3/10A61P 37/02A61P 9/00A61P 37/00A61P 37/06A61P 35/00A61P 7/04A61P 5/14A61P 7/06A61P 37/08A61P 25/00A61P 29/00A61P 25/02G01N 2800/065A61P 1/04A61P 11/06A61P 13/12A61P 17/02C07K 2319/00G01N 2333/705A61P 19/02G01N 2800/24A61P 21/00G01N 2800/245C07K 16/28A61P 1/00A61P 11/00A61K 38/00A61P 17/00G01N 33/6893C07K 14/705G01N 33/5011A61P 17/04A61P 17/06A61P 11/02A61P 1/16G01N 33/57557
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.

Claims

exact text as granted — not AI-modified
1 .- 3 . (canceled) 
     
     
         4 . A method of alleviating a T cell mediated disease characterized by stimulation of T cell proliferation in a mammal comprising administering to said mammal a therapeutically effective amount of an agonist antibody that specifically binds to the polypeptide of SEQ ID NO:2 and inhibits T cell proliferation. 
     
     
         5 . The method of  claim 4 , wherein the T cell mediated disease is an autoimmune disease. 
     
     
         6 . The method of  claim 4 , wherein the T cell mediated disease is selected from rheumatoid arthritis (RA); asthma; psoriasis; multiple sclerosis (MS); inflammatory bowel disease (IBD); systemic lupus erythematosus (SLE); and graft-versus-host disease (GVHD). 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 4 , wherein the agonist antibody is a monoclonal antibody. 
     
     
         9 . The method of  claim 4 , wherein the agonist antibody is an antibody fragment. 
     
     
         10 . The method of  claim 9 , wherein the antibody fragment is a single-chain antibody. 
     
     
         11 . The method of  claim 9 , wherein the antibody fragment is a Fab, Fab′, F(ab′) 2 , or Fv fragment. 
     
     
         12 . The method of  claim 4 , wherein the agonist antibody is a humanized antibody. 
     
     
         13 . The method of  claim 4 , wherein the agonist antibody is an isolated human antibody. 
     
     
         14 . The method of  claim 4 , wherein the agonist antibody specifically binds to amino acids 1-155 of SEQ ID NO:2. 
     
     
         15 . The method of  claim 4 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2012171208A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.